1 / 44

Cal-X stars Business Accelerator 2013 Portfolio

Cal-X stars Business Accelerator 2013 Portfolio . 50% Life Science with stem cell focus 50% short term cash flow producing businesses. Cal-X Stars . 4 to 8 companies in 12 week programs 4X a year. $6K invested in each full time founder in 12 wk program. 20 companies in 5 year program.

dale
Télécharger la présentation

Cal-X stars Business Accelerator 2013 Portfolio

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cal-X stars Business Accelerator 2013 Portfolio 50% Life Science with stem cell focus 50% short term cash flow producing businesses

  2. Cal-X Stars • 4 to 8 companies in 12 week programs 4X a year. • $6K invested in each full time founder in 12 wk program. • 20 companies in 5 year program. • Average investment $1 to $7 million per co. 5 yr program. • Backed primarily by Leonhardt Ventures - $145 mil. put to work so far. • 50% breakthrough stem cell innovations. • Allows innovators to focus on innovation. • Balances long term stem cell developments with cash producing businesses.

  3. The California Stock Exchange • Goal to be the third major exchange in the USA with a focus on smaller offerings and smaller firms. • We only accept conscious capitalism companies. • We feature, promote and facilitate local investing.  We are trying to get all Starbucks and Whole Foods to post local cos looking for funding as an example.  • We promote social impact investing. • We promote super high levels of transparency. • No day trading!  No short trading!  Sell orders take up to 90 days to fill for price stabilization!  • Comprehensive research on all companies. • The first NURTURING EXCHANGE - we do not just list companies we nurture them, mentor them, guide them, help them - so do all our members.

  4. Bioheart, Inc. • Bioheart, Inc. www.bioheartinc.com - muscle stem cells delivered via a needle tipped catheter into post heart attack heart tissue to grow bands of new blood pumping muscle. • Heart failure is the leading cause of hospitalization with more than 50 million people affected. • No other treatment addresses the underlying problem of recovering post heart attack scar tissue to beating pumping new muscle until Bioheart’sMyoCell. • 4 clinical trials have been completed and published already. The most recent Phase II/III study demonstrated 95.7 meters improvement in exercise capacity for BioheartMyoCell treated patients over placebo (minus 4 meters decline). This beat our primary study end point goal of 16 meters improvement by over 500%. • $8 billion is spent on heart failure drugs each year which provide only minus 4 meters decline. CRT Heart Pacers with over $6 billion in sales provide only 16 meters improvement. No other stem cell type studied to date has demonstrated an ability to better 53 meters improvement. BioheartMyoCell is the only stem cell composition that has demonstrated an ability to grow new contractile muscle in heart scar tissue. Cost of product: $1000 Sell Price: $23,000 Market: 50 million heart failure patients worldwide. Expected Sales After Full Launch: $5 billion annually.

  5. Myoblast Engraftment Post-Transplantation Human Heart, Proof of Concept Contractile muscle tissue growing in the scarred portion of the heart following treatment with myoblast injections. * Hagege et al., Viability and Differentiation of Autologous Skeletal Myoblast Grafts in Ischemic Cardiomyopathy, Lancet, Vol. 361, 2003: 491-492

  6. MyoCell: Heart Failure Treatment Process 2 Cell manufacturing following thigh muscle biopsy Injection of skeletal myoblasts into scar tissue using deflecting-tip catheter 3 Scar tissue following heart attack 1

  7. MARVEL-1: Mean Change in 6-Minute Walk Distance (meters) n=6 n=7 n=6 p=0.50

  8. MyoStim Pacemaker MyoStim

  9. MyoStim pacers • MyoStim Pacers www.myostimpacers.com - World’s first heart failure pacemaker with capability to recruit via a homing signal stem cells to damaged heart tissue and to differentiate those stem cells into muscle. • Boston Scientific bought Guidant for $27 billion a few years ago to gain access to their heart failure pacemaker that only increase the pumping ability of un-damaged heart tissue and does nothing to recover post heart attack scar tissue. The MyoStim Pacer is the first with the ability to recover heart scar tissue. • The company also has a quicker to market electrical stimulator for diabetic foot ulcer wound healing. Cost of product: $1000 Sell price: $23,000 for heart product. Cost of product: $1000 Sell price: $4500 for wound healing product. Market size: 75 million patients worldwide. Expect Sales After Full Launch: $2 billion annually

  10. Stem Cell bra • StemCellBrawww.stemcellbra.com - The World’s first women’s bra designed to recruits her own stem cells to her breast tissue to augment fullness without surgery. • The bra has a conductive gelatin liner and is connect via two small wires to an electrical stimulator worn at the belt line that is about the size of a cell phone. • The product is destined to increase breast cup size by one size every 12 weeks of use. • The StemCell Bra team is working with Dr. Joel Aronowitz arguably the world’s leading breast reconstruction surgeon. He recently utilized stem cell based treatments to successfully treat the actress Suzanne Sommer’s breast in recovery from cancer. • StemCellBrahas a working collaboration with BioCell Therapies of Minneapolis that has developed a method and kits for collecting and using stem cells extracted from fat tissue combined with fat tissue for breast reconstruction. Cost of product: $400 Sell price: $2000 Market: Over 1 billion women worldwide. Expected Annual Sales After Full Launch: $10 billion

  11. Heart pump cath • Heart Pump Cath – www.heartpumpcath.com - The company and it’s affiliated partners have developed three models of heart pumps on catheters. • The first is set to go to market in Europe 2Q 2013 and to be approved for sale in the USA by 3Q 2013. Data from clinical trials in Europe demonstrate a 33% improvement in cardiac output • an substantial improvement of renal function in treated patients. This competes against the AbiomedImpella which achieved $160 million in revenues that past 12 months. It also competes the large Intra Aortic Balloon Pump market that exceeds $500 million. • The 2nd and 3rd generation Heart Pump Caths feature nitinol assemblies which permit a heart pump to be staged assembled within an aorta. This design allows for the lowest profile percutaneous catheter delivery combined with the highest flow rate pump. We intend to partner with and invest in two related companies Cardiobridge • www.cardiobridge.com and Procyrionwww.procyrion.com. Both have developed aortic temporary pump systems complimentary to our own. Cost of product: $1000 Sell Price: $25,000 Market: 25 million advanced heart failure patients worldwide. Expected Annual Sales After Full Launch: $500 million.

  12. Heart score • HeartScore – www.heartscore.com- • Do you know your HeartScore? • The company has developed a composite single number scoring system for heart disease risk. • The composite components come from a series of genetic tests, blood tests, a lifestyle questionnaire and monitoring program and an artery scan. All enrolled into the program receive a SecondBeat watch which has an infrared scanner that determines blood vessel inner endothelium wall health on a real time basis. • If you sit all day and eat hamburgers your risk score displayed on the watch face will go higher and if you exercise and eat healthy foods your risk score will lower – all real time. We intend to work with Dr. Clyde Yancy of the Heart Failure Society of America (HFSA)to implement a compliance monitoring system that ensures compliance with all HFSA guidelines to reduce un-necessary hospitalizations from heart failure. We complete this in partnership with @ home heart failure monitoring technology provided by NI Medical of Israel. Cost of program: $40 a month. Sell price program: $100 to $400 a month. Market: 50 million heart failure patients worldwide and 1 billion people worldwide that can afford to monitor their heart disease risk with commitment to their own health. Expected Annual Sales after full launch: $400 million

  13. biopace • BioPace – The World’s first biological pacemaker made of living cells just the way our natural pacemakers work. • Natural living cell pacemakers outperform steel can battery powered electronic pacemakers with implantable steel leads by a long margin of reliability. • Over $8 billion of battery powered artificial pacemakers are sold each year. • The BioPace technology may also be used to treat A-Fib as an alternative to burning of freezing tissue ablation procedures. • Approximately $800,000 has been invested to date to advance this platform to market. A number of patents have been issued and/or licensed. Cost of Product: $400 Sell Price: $6000 Market: 100 million patients worldwide Expected Annual Sales After Full Launch: $2 billion

  14. Aorta-cell • AortaCell – Utilizing muscle stem cells to strengthen weakened aortic walls to treat small aneurysms before they become a rupture risk. • Treating the necks of aneurysms where stent grafts are placed to reduce risk of neck dilatation and device leaking. • A non-invasive electrical signal belt that treats aortic wall tissue. • Our core team introduced innovations in this field in the late 1990’s that led to market leadership positions with the TALENT stent graft. We are now ready to obsolete our own technologies. Aortic blood vessels are made of living cells and are best repaired by living cells. Cost of product: $2000 Sell Price: $23,000 Market: 1 million aneurysms diagnoses worldwide annually. Expected Annual Sales After Full Launch: $800 million

  15. Endo-cell • EndoCell – Utilizing endothelial progenitor cells derived from fat tissue to repair damaged artery walls utilizing an adventia needle delivery catheter. • Cost of Product: $2000 Sell Price: $6,000 Market: 100 million+ arterial disease patients worldwide. Expected Annual Sales after Full Launch: $600 million

  16. Coro-stim • CoroStim – Utilizing vibrational energy to avoid arterial plaque formation in coronar arteries in high risk patients. • A boat hall vibrated does not have barnacles. The same principle applies here. • Cost of product: $1400 Sell Price: $12,000 Market: $10 million+ high risk patients worldwide Expected Annual Sales after Full Launch: $100 million

  17. Myovalve & valvulblator • Apparatus and method to remove plaque from heart valve leaflets, spray on a scaffolding material and cell seed leaftlets. • Allows patients to keep their own heart valve instead of getting an artificial implant.

  18. Other holdings • Degreed.com – College credit for every form of learning. • Roozt.com – Cause brand marketplace. • Cheryl Fudge – The build a bear of fashion. • KindheartLionheart – Inspirational books. • KindheartLionheart Adventures – Charity travel co. • Food Trikes & Scooters – Empowering entrepreneurs. • Wine Country Baseball – Cape Cod League of West. • Test Prep Vids – Quick test prep phone downloads. • Crowdfunder.com – Crowdfunding site. • SocMe Academy – Teaching social media to companies. • Cal Xport – California export assistance.

  19. Crowdfundtv show • Live TV crowdfunding. • Expected to air Tuesday and Thursday primetime on CNBC. • Produced by Go Go Luckey • Format similar to The Voice except Startups. • 3 companies per hour. • 3 mentors, hosts, judges. • Each mentor introduces a company they are mentoring. • May forever change television.

More Related